ArticleBMC gastroenterology2026
Clinicopathological characteristics and prognostic outcomes in consecutive Japanese patients with high microsatellite-instability colorectal cancer: real-world data from universal screening.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh microsatellite instability (MSI-H) is an established prognostic marker in various cancers, including colorectal, gastric, and endometrial cancers. However, comprehensive real-world data from universal screening in Asian populations remain limited. We aimed to evaluate the clinicopathological and prognostic impact of MSI-H status in Japanese patients with colorectal cancer (CRC).
methodsThis retrospective cohort study was conducted at Osaka General Medical Center, Japan. A total of 346 consecutive patients with CRC who underwent MSI testing between January 2021 and December 2022 were retrospectively analyzed. MSI status and associated clinicopathological features were assessed. Overall survival (OS) and recurrence-free survival (RFS) were analyzed using Kaplan–Meier survival curves and Cox regression models.
resultsAmong the 346 patients, 29 (8.4%) had MSI-H tumors, which were more frequently right-sided (p <0.0001) and poorly differentiated (p <0.0001) compared with non-MSI-H. Genomic analysis revealed that MSI-H tumors had significantly fewer RAS mutations (p = 0.024) and more BRAF mutations (p <0.0001) compared with non-MSI-H tumors. Survival analysis showed no significant differences in RFS (HR, 0.67; 95% CI, 0.26–1.90; p = 0.40) or OS (HR, 0.64; 95% CI, 0.30–1.58; p = 0.78) between patients with MSI-H and non–MSI-H tumors. Multivariate analysis identified MSI-H as a potential independent predictor of favorable OS (HR, 0.07; 95% CI, 0.005–0.90; p = 0.04), whereas BRAF mutations were associated with poor OS (HR, 7.39; 95% CI, 1.32–41.50; p = 0.02).
conclusionsThis real-world study suggests that MSI-H status is associated with distinct clinicopathological characteristics and may be associated with improved overall survival in Japanese patients with CRC undergoing universal MSI screening. These findings support the clinical relevance of MSI testing in routine clinical practice and highlight the need for further validation in a larger cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.